Initiate Phase I clinical development of oral checkpoint inhibitor CCX559 for cancer
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 1 Mar 2021
- Due
- 30 Jun 2021
- Delivered
- Q2 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company remains on track to initiate Phase I clinical development of its orally administered checkpoint inhibitor, CCX559, for cancer in the first half of 2021”
What we found
Evidence strength A What the grades mean
Later filings state the company initiated a Phase I trial of CCX559 in the second quarter of 2021, within the first-half-2021 deadline.
-
A ChemoCentryx, Inc. 8-K filed 2021-08-09
“In Q2, the Company initiated Phase I clinical development of CCX559, a novel, orally-administered, PD-1/PD-L1 checkpoint inhibitor.” ✓ confirmed on the page
-
A ChemoCentryx, Inc. 10-Q filed 2021-08-09
“We initiated a Phase I clinical trial of CCX559 in the second quarter of 2021.” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Initiate
- Deliverable
- Phase I clinical development of CCX559 for cancer
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you ChemoCentryx, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C340652-024852 · Corrections policy